A complete oral regimen for induction therapy of patients with high‐risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy

• Published in: British journal of haematology Vol. 205; no. 2; pp. 510 - 516
• Main Authors: Tang, Fei‐Fei, Duan, Wen‐Bing, Liu, Xiao‐Hong, Lu, Sheng‐Ye, Zhao, Xiao‐Su, Qin, Ya‐Zhen, Jia, Jin‐Song, Wang, Jing, Gong, Li‐Zhong, Jiang, Qian, Zhao, Ting, Shi, Hong‐Xia, Chang, Ying‐Jun, Huang, Xiao‐Jun, Jiang, Hao
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.08.2024
• Subjects: acute promyelocytic leukaemia; Arsenic; Chemotherapy; completely oral; COVID-19; Cytotoxicity; Etoposide; Induction therapy; Intravenous administration; Remission; Retinoic acid; Survival; VP16 protein; etoposide; acute promyelocytic leukaemia; completely oral

Summary There is an urgent need for an oral, efficient and safe regimen for high‐risk APL under the pandemic of COVID‐19. We retrospectively analysed 60 high‐risk APL patients. For induction therapy (IT), in addition to all‐trans retinoic acid (ATRA) and oral arsenic (RIF), 22 patients received oral...